Industry
Biotechnology
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
April 03, 2024 | 12:07 pm
Portfolio Pulse from Happy Mohamed
March 28, 2024 | 3:45 am
Portfolio Pulse from Benzinga Newsdesk
March 27, 2024 | 8:38 pm
Portfolio Pulse from Benzinga Newsdesk
March 07, 2024 | 4:26 pm
Portfolio Pulse from Benzinga Insights
March 05, 2024 | 5:00 pm
Portfolio Pulse from Benzinga Newsdesk
March 05, 2024 | 3:50 pm
Portfolio Pulse from Benzinga Newsdesk
February 07, 2024 | 12:57 pm
Portfolio Pulse from Benzinga Newsdesk
January 29, 2024 | 2:06 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.